LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that it has released Version 7.2 of its best-in-class ADMET Predictor™ molecular property prediction software.
Dr. Robert Clark, director of cheminformatics at Simulations Plus, said, “The latest release of ADMET Predictor contains updated cytochrome P450 kinetics models that are seamlessly integrated into the recently released GastroPlus™ Version 9.0, enhancing our synergy between predicted properties and PBPK simulations. It also contains two new models related to human liver microsome (HLM) stability, an experiment that is routinely run on newly synthesized compounds in the pharmaceutical industry.”
Dr. Michael Lawless, business development manager for cheminformatics solutions, added, “Our cytochrome P450 kinetics models have been improved by additional data curation. The updated models illustrate our commitment to providing the best predictive models in the industry. The new HLM intrinsic clearance model was built using literature data from roughly 1,500 molecules published by pharmaceutical industry scientists. Thus, the model’s chemistry space is highly relevant to lead discovery.”
John DiBella, vice president for marketing and sales, added, “ADMET Predictor enjoys an outstanding reputation for speed and accuracy, providing chemists with a tool that lets them predict over 150 properties of molecules from just their structure drawings. This capability means chemists can filter through huge numbers of virtual molecules and eliminate the majority based on high ADMET Risk™ without the need to synthesize and test them. The cost and time savings realized from high-quality property predictions is substantial.”
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus also recently acquired Cognigen Corporation of Buffalo, New York, adding top-quality statistical modeling and simulation using clinical trial data to its offerings, as well as more than doubling their staff from 30 to over 60, adding nearly 50% to revenues, and increasing earnings in the fiscal year that began September 1, 2014. The Company is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” Cognigen Corporation remains located in Buffalo, NY. For more information, visit our web site at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect,” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.
